TABLE 3.
TAF antiviral activities against human viruses
| Virus | TAF |
Tenofovir |
Positive control | ||
|---|---|---|---|---|---|
| EC50 (nM) | CC50 (nM) | EC50 (μM) | CC50 (μM) | ||
| HIV-1 NL4-3 | 5.8 | >1,000 | 2.3 | >100 | AZT |
| HIV-1 BaL | 2.0 | >1,000 | 1.0 | >100 | AZT |
| SIV mac239 | 1.21 | >1,000 | 0.73 | >1,000 | AZT |
| SIV mac251 | 0.51 | >1,000 | 0.35 | >1,000 | AZT |
| Adenovirus | >1,000 | >1,000 | >1,000 | >1,000 | Ribavirin |
| Dengue virus | >1,000 | >1,000 | >1,000 | >1,000 | Ribavirin |
| Hepatitis C virus | >1,000 | >1,000 | >1,000 | >1,000 | rIFN-αe |
| Coxsackie B virus | >1,000 | >1,000 | >1,000 | >1,000 | Enviroxime |
| Rhinovirus | >1,000 | >1,000 | >1,000 | >1,000 | Enviroxime |
| Vaccinia virus | >1,000 | >1,000 | >1,000 | >1,000 | Cidofovir |
| Influenza A virus | >1,000 | >1,000 | >1,000 | >1,000 | Zanamivir |
| Human parainfluenza virus | 843 | >1,000c | >1,000 | >1,000 | Enviroxime |
| Respiratory syncytial virus | >1,000 | >1,000 | >1,000 | >1,000 | Ribavirin |
| VZVa | >1,000 | >1,000 | >1,000 | >1,000 | Acyclovir |
| HCMVb | >1,000 | >1,000 | >1,000 | >1,000 | Ganciclovir |
| HSV-1 | >1,000 | >1,000 | >1,000d | >1,000 | Acyclovir |
| HSV-2 (KW) | 424 | >1,000 | 146 | >1,000 | Acyclovir |
| HSV-2 (MS) | 697 | >1,000 | 278 | >1,000 | Acyclovir |
a
VZV, varicella-zoster virus.
b
HCMV, human cytomegalovirus.
c
Cell growth inhibition was observed at the highest concentration.
d
Viral inhibition was observed at the highest concentration.
e
rIFN-α, recombinant alpha interferon.